NASDAQ:BFRI Biofrontera (BFRI) Stock Forecast, Price & News $8.49 -0.25 (-2.86%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$8.48▼$8.8250-Day Range$8.09▼$12.3452-Week Range$7.41▼$25.80Volume2,670 shsAverage Volume11,478 shsMarket Capitalization$11.63 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Biofrontera MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside112.0% Upside$18.00 Price TargetShort InterestHealthy2.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($15.78) to ($6.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector531st out of 966 stocksPharmaceutical Preparations Industry236th out of 434 stocks 3.5 Analyst's Opinion Consensus RatingBiofrontera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.00, Biofrontera has a forecasted upside of 112.0% from its current price of $8.49.Amount of Analyst CoverageBiofrontera has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.65% of the float of Biofrontera has been sold short.Short Interest Ratio / Days to CoverBiofrontera has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biofrontera has recently increased by 9.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiofrontera does not currently pay a dividend.Dividend GrowthBiofrontera does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BFRI. Previous Next 1.9 News and Social Media Coverage News SentimentBiofrontera has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Biofrontera this week, compared to 1 article on an average week.Search Interest1 people have searched for BFRI on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biofrontera insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.64% of the stock of Biofrontera is held by insiders.Percentage Held by Institutions58.40% of the stock of Biofrontera is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Biofrontera are expected to grow in the coming year, from ($15.78) to ($6.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biofrontera is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biofrontera is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiofrontera has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Biofrontera (NASDAQ:BFRI) StockBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription drug for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts.Read More BFRI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BFRI Stock News HeadlinesSeptember 18, 2023 | msn.comAll You Need to Know About Biofrontera Inc. (BFRI) Rating Upgrade to BuyAugust 28, 2023 | finanznachrichten.deBiofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of AmeluzOctober 4, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.August 28, 2023 | finance.yahoo.comBiofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)August 10, 2023 | benzinga.comEarnings Outlook For BiofronteraAugust 4, 2023 | finance.yahoo.comBiofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023July 13, 2023 | finance.yahoo.comBiofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%July 12, 2023 | finance.yahoo.comBiofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of DirectorsOctober 4, 2023 | Goldco (Ad)Biden's Digital Dollar NightmareOn July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late! June 1, 2023 | finanznachrichten.deBiofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz-PDTMay 30, 2023 | finance.yahoo.comBiofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive OfficerMay 15, 2023 | finance.yahoo.comBiofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side EffectsMay 12, 2023 | finance.yahoo.comBiofrontera Inc. (BFRI) Reports Q1 Loss, Misses Revenue EstimatesMay 12, 2023 | msn.comBiofrontera reports misses Q1 top and bottom consensus; reaffirms FY23 outlookMay 12, 2023 | finance.yahoo.comBiofrontera Inc. Announces Resignation of CEOMay 12, 2023 | finance.yahoo.comBiofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business UpdateMay 9, 2023 | finance.yahoo.comBiofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer PreventionApril 28, 2023 | finance.yahoo.comBiofrontera Inc. to Report First Quarter 2023 Financial Results on May 12, 2023April 26, 2023 | finance.yahoo.comBiofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)April 3, 2023 | nasdaq.comBiofrontera Inc. Common Stock (BFRI)March 27, 2023 | finance.yahoo.comBiofrontera Inc. Makes Transformative Investment in Its' Dermatology SalesforceMarch 17, 2023 | finance.yahoo.comBiofrontera Inc. to Attend 2023 American Academy of Dermatology Annual MeetingMarch 11, 2023 | finance.yahoo.comBiofrontera Inc. (NASDAQ:BFRI) Analysts Just Slashed Next Year's EstimatesMarch 10, 2023 | finance.yahoo.comBiofrontera Inc. (NASDAQ:BFRI) Q4 2022 Earnings Call TranscriptMarch 9, 2023 | finance.yahoo.comCORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial ResultsMarch 8, 2023 | finance.yahoo.comBiofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial ResultsMarch 2, 2023 | finance.yahoo.comBiofrontera, Inc. to Present at the 35th Annual ROTH Conference on March 13, 2023See More Headlines Receive BFRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter. Email Address BFRI Company Calendar Last Earnings8/11/2023Today10/03/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BFRI CUSIPN/A CIK1858685 Webwww.biofrontera-us.com Phone781-245-1325FaxN/AEmployees81Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.00 High Stock Price Forecast$18.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside+112.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($17.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-640,000.00 Net Margins-78.03% Pretax Margin-77.96% Return on Equity-126.98% Return on Assets-48.37% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio0.69 Sales & Book Value Annual Sales$28.67 million Price / Sales0.41 Cash FlowN/A Price / Cash FlowN/A Book Value$17.89 per share Price / Book0.47Miscellaneous Outstanding Shares1,370,000Free Float1,359,000Market Cap$11.63 million OptionableNot Optionable Beta1.09 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Hermann Luebbert Ph.D. (Age 67)Chairman, CEO & Pres Comp: $476.36kMr. Eugene Fredrick Leffler III (Age 39)Chief Financial Officer Comp: $316.32kMs. Erica F. Gates CPAM.B.A., Sr. Director of Fin. & Principal Accounting OfficerMr. Jon Lyons M.B.A.Ph.D., VP of Scientific & Medical AffairsMs. Alycia TorresVP of Admin.Mr. Daniel Hakansson J.D.Gen. Counsel & Head of ComplianceMs. Samantha WiddicombeSr. Director of Strategic Accounts & CommunicationsMr. Mark BaldygaVP of & MarketingMr. Anthony TakazawaExec. OfficerMore ExecutivesKey CompetitorsDominariNASDAQ:DOMHPasithea TherapeuticsNASDAQ:KTTATFF PharmaceuticalsNASDAQ:TFFPImpel PharmaceuticalsNASDAQ:IMPLMoleculin BiotechNASDAQ:MBRXView All CompetitorsInstitutional OwnershipBlackRock Inc.Sold 39,370 shares on 8/11/2023Ownership: 6.949%Geode Capital Management LLCSold 1,815 shares on 8/11/2023Ownership: 6.111%Renaissance Technologies LLCBought 14,700 shares on 8/11/2023Ownership: 3.792%Simplex Trading LLCBought 300 shares on 8/4/2023Ownership: 0.000%View All Institutional Transactions BFRI Stock - Frequently Asked Questions Should I buy or sell Biofrontera stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BFRI shares. View BFRI analyst ratings or view top-rated stocks. What is Biofrontera's stock price forecast for 2023? 1 Wall Street research analysts have issued twelve-month price objectives for Biofrontera's shares. Their BFRI share price forecasts range from $18.00 to $18.00. On average, they expect the company's share price to reach $18.00 in the next year. This suggests a possible upside of 112.0% from the stock's current price. View analysts price targets for BFRI or view top-rated stocks among Wall Street analysts. How have BFRI shares performed in 2023? Biofrontera's stock was trading at $18.3320 at the beginning of the year. Since then, BFRI stock has decreased by 53.7% and is now trading at $8.49. View the best growth stocks for 2023 here. Are investors shorting Biofrontera? Biofrontera saw a increase in short interest in September. As of September 15th, there was short interest totaling 21,000 shares, an increase of 9.4% from the August 31st total of 19,200 shares. Based on an average daily volume of 16,600 shares, the short-interest ratio is presently 1.3 days. Approximately 2.7% of the company's stock are sold short. View Biofrontera's Short Interest. When is Biofrontera's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our BFRI earnings forecast. How were Biofrontera's earnings last quarter? Biofrontera Inc. (NASDAQ:BFRI) released its quarterly earnings results on Friday, August, 11th. The company reported ($6.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.14) by $1.00. The business earned $5.85 million during the quarter, compared to analyst estimates of $5.86 million. Biofrontera had a negative trailing twelve-month return on equity of 126.98% and a negative net margin of 78.03%. When did Biofrontera's stock split? Shares of Biofrontera reverse split on the morning of Wednesday, July 5th 2023. The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What guidance has Biofrontera issued on next quarter's earnings? Biofrontera updated its FY 2023 earnings guidance on Sunday, September, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $35.84M-. When did Biofrontera IPO? (BFRI) raised $19 million in an initial public offering on Friday, October 29th 2021. The company issued 3,100,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company served as the underwriters for the IPO. What is Biofrontera's stock symbol? Biofrontera trades on the NASDAQ under the ticker symbol "BFRI." How do I buy shares of Biofrontera? Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biofrontera's stock price today? One share of BFRI stock can currently be purchased for approximately $8.49. How much money does Biofrontera make? Biofrontera (NASDAQ:BFRI) has a market capitalization of $11.63 million and generates $28.67 million in revenue each year. The company earns $-640,000.00 in net income (profit) each year or ($17.83) on an earnings per share basis. How can I contact Biofrontera? The official website for the company is www.biofrontera-us.com. The company can be reached via phone at 781-245-1325 or via email at us-ir@biofrontera.com. This page (NASDAQ:BFRI) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.